A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-VOYAGER)

Inclusion Criteria: Age ≥ 18 years to 54 years with a diagnosis of AD according to the American Academy of Dermatology (AAD) Consensus Criteria (2014) present for at least 12 months History of inadequate response to topical corticosteroids (TCS) of medium or higher potency (with or without topical calcineurin inhibitors) Validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3 Exclusion Criteria: Treatment with a biologic product within 12 weeks or 5 half-lives, whichever is longer, prior to Day 1 Treatment with any of the following medications or therapies within 4 weeks or 5 half-lives, whichever is longer, prior to Day 1: Systemic corticosteroids Systemic immunosuppressants Phototherapy Janus kinase inhibitors Treatment with any of the following medications or therapies within 1 week, prior to Day 1: TCS Topical calcineurin inhibitors (TCI) Anti-pruritic agents or antihistamines used for treatment of pruritis Topical Phosphodiesterase-4 inhibitors (PDE4) Other topical immunosuppressive agents Combination topical agents containing a corticosteroid or calcineurin inhibiting component, PDE4 inhibitors, or other topical immunosuppressive agents Treatment with live virus including live attenuated vaccination 12 weeks prior to day 1 pre-randomization. Inactivated vaccination (eg, non-live or nonreplicating agent), including coronavirus disease 2019 (COVID-19) vaccination, is allowed. Treatment with any meningococcal vaccine within 1 year prior to screening, or treatment with any tetanus-, diphtheria-, or pertussis containing vaccine within 5 years prior to screening